Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Brigo, Francesco ^a   Igwe, Stanley C ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b Federal Teaching Hospital   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

STIRIPENTOL; 1,3 DIOXOLANE DERIVATIVE; ANTICONVULSIVE AGENT;

ADD ON THERAPY; ADVERSE EVENT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFANT; KETOGENIC DIET; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SYSTEMATIC REVIEW; ADOLESCENT; CHILD; EPILEPSIES, MYOCLONIC; FEMALE; MALE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURES;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DIOXOLANES; EPILEPSIES, MYOCLONIC; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES;

EID: 84979865425     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010483.pub3     Document Type: Review

References (22)

1. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO Study Group. Lancet 2000;356(9242):1638-42.
2. Guerrini R, Tonnelier S, d'Athis P, Rey E, Vincent J, Pons G. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia 2002;43(Suppl 8):155.
3. Chiron C. Stiripentol. Expert Opinion on Investigational Drugs 2005;14:905-11.
4. Chiron C. Stiripentol. Neurotherapeutics 2007;4:123.
5. Chiron C, Kassai B, Dulac O, Pons G, Nabbout R. A revisited strategy for antiepileptic drug development in children: designing an initial exploratory step. CNS Drugs 2013;27(3):185-95.
6. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome. Advances in Neurology 2005;95:71-102.
7. Fisher JL. The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology 2009;56:190-7.
8. Fujiwara T, Sugawara T, Mazaki-Miyazaki E, Takahashi Y, Fukushima K, Watanabe M, et al. Mutations of sodium channel alpha subunit type 1(SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain 2003;126:531-46.
9. Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metabolism and Disposition 2006;34:608-11.
10. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
11. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
12. Hurst DL. Epidemiology of severe myoclonic epilepsy in infancy. Epilepsia 1990;31:397-400.
13. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:289-99.
14. Kassai B, Chiron C, Augier S, Cucherat M, Rey E, Gueyffier F, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia 2008;49(2):343-8.
15. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, Williamson PR. impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c356.
16. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069-77.
17. Nabbout R, Gennaro E, Dalla Bernardina B, Dulac O, Madia F, Bertini E, et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology 2003;60:1961-7.
18. Perez J, Chiron C, Musial C, Rey E, Blehaut H, d'Athis P, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia 1999;40:1618-26.
19. Quilichini PP, Chiron C, Ben-Ari Y, Gozlan H. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 2006;47:704-16.
20. Yakoub M, Dulac O, Jambaque I, Chiron C, Plouin P. Early diagnosis of severe myoclonic epilepsy in infancy. Brain and Development 1992;14:299-303.
21. Brigo F, Storti M, Del Felice A. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010483]
22. Brigo F, Storti M. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010483.pub2;: ]